Results 71 to 80 of about 166 (149)
Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis +4 more
wiley +1 more source
Immunopharmacology 2020. V International Congress on Immunopharmacology
VacciMonitor, 2020 The Organizing Committee of the “V International Congress on Immunopharmacology” (Immunopharmacology 2020) organized by the Cuban Society of Pharmacology, BioCubaFarma and the International Union of Basic and Clinical Pharmacology (IUPHAR) would like to ...
Mario Landys Chovel Cuervo, Silvio Perea
doaj
Denosumab discontinuation and fracture risk: getting the balance right
Internal Medicine Journal, EarlyView.Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley +1 more source
Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis
Frontiers in PharmacologyBiosimilar tumor necrosis factor inhibitors provide therapeutically equivalent alternatives to reference biologics for ankylosing spondylitis (AS) management at reduced costs.
Luoyang Cai +6 more
doaj +1 more source
Clinical Pharmacology & TherapeuticsThere are no clinically meaningful differences between bio‐originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4 mL/no ...
Amy C.D. Peeters +7 more
openaire +3 more sources
From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry [PDF]
Technological Forecasting and Social Change, 2019 Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology ...
openaire +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
The Laryngoscope, Volume 136, Issue S4, Page S7-S17, September 2026.ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best +17 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8602-8612, September 2026.ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan +26 more
wiley +1 more source
Cancer, Volume 132, Issue 16, 15 August 2026.ABSTRACT Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively ...
Daniel J. DeAngelo +15 more
wiley +1 more source